Category: Regulatory DisclosuresBy adminNovember 15, 2023 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Rameda Reports its 3Q23 ResultsNextNext post:Rameda Maintains its Impressive Momentum with the Launch of a New Type 2 Diabetes Product, Bolstering its Chronic PortfolioRelated PostsBOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024Rameda 4Q23 BOD Meeting MinutesMarch 18, 2024BOD Report FY2023- under the Regulatory DisclosuresMarch 18, 2024Annual Corporate Governance Disclosure ReportMarch 18, 2024
